# A Phase II Study of an Anti-Tumor Immunotherapy Regimen Comprised of Pegylated Interferon-Alpha 2b and HyperAcute Melanoma Vaccine for Subjects With Advanced Melanoma

> **NCT00746746** · PHASE2 · UNKNOWN · sponsor: **Ochsner Health System** · enrollment: 30 (estimated)

## Conditions studied

- Melanoma

## Interventions

- **BIOLOGICAL:** HyperAcute vaccine
- **DRUG:** Pegylated Interferon-Alpha 2b

## Key facts

- **NCT ID:** NCT00746746
- **Lead sponsor:** Ochsner Health System
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2008-06
- **Primary completion:** 2010-06
- **Final completion:** 2011-06
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2011-01-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00746746

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00746746, "A Phase II Study of an Anti-Tumor Immunotherapy Regimen Comprised of Pegylated Interferon-Alpha 2b and HyperAcute Melanoma Vaccine for Subjects With Advanced Melanoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00746746. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*